MedTrace Logo

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

NCT03091127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 705

Last updated 2022-12-12

No results posted yet for this study

Summary

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting.

This study will therefore provide essential data to demonstrate the real world utilization of carfilzomib in routine clinical practice, including dosage, administration schedule, regimen, duration of treatment and reason for discontinuation in Europe.

Conditions

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-14
Primary Completion
2020-03-17
Completion
2020-03-17

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • France
  • Greece
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03091127 on ClinicalTrials.gov